Atlangram - Preclinical Contract Research Organisation

About Us Our Team Our Partners

About Us

ATLANGRAM is based in France at the Medicine School of Nantes. Our company is a preclinical Contract Research Organisation (CRO) specializing in efficacy testing of antimicrobials.

Our offer is comprehensive and consists of a wide range of microbiology studies to assess the in vitro and in vivo activities of an antimicrobial agent.

The objectives are to obtain consistent, coherent and reproducible results with respecting the classical steps of Drug Development: preliminary in vitro testing, preliminary in vivo screening models (mice sepsis and thigh models), efficacy models (pneumonia, acute osteomyelitis, endocarditis, urinary tract infection) and simulation of the human PK (in rabbit, using modeling software).

Thus, we can provide recommendations on optimal dose, on administration route and/or frequency, and finally, on bacterial targets and future development/indications of the compound.

  • ATLANGRAM has developed and uses a modeling software to simulate human PK/PD in animals.
  • As a partner, ATLANGRAM is interested in developing cooperative and collaborative relationships.
  • ATLANGRAM has been accredited for the French R&D tax credit (Crédit d’Impôt Recherche, CIR) by the French Ministry of Higher Education and Research.

 

Download our brochure

 

Our Team

ATLANGRAM scientific team is composed of clinicians and / or biologists researchers whose professional paths, skills and experiences are complementary.

 

MANAGEMENT
Professeur Amokrane

Dr. Amokrane REGHAL (M.D, Microbiologist)

Chief Executive Officer. Co-founder.

Amokrane is a Medical Microbiologist and worked more than 15 years in the pharmaceutical industry as successively: Medical Adviser (ciprofloxacin and moxifloxacin: Bayer), Regional Director (10 Medical Representatives,Bayer), MSL Director (7 MSL, Pfizer).

 
SCIENTIFIC BOARD

Pr. Gilles POTEL (Full Professor & Hospital Practitioner)

President of the Scientific Board & Clinical Advisor. Co-founder.

Gilles P. is a Therapeutics Professor since 1995 and is Responsible of the teaching of Therapeutics at the Medicine Faculty of Nantes, and Director of the Research Unit “Clinical and Experimental Therapeutics of Infections" (EA 3826) since 2000. Gilles is a member (1999) and President of the Medical Commission of the Nantes Hospital since 2009 and Head of the Emergency Service since 2003. Gilles got an Accreditation to supervise research in 1993.

 

Dr. Jocelyne CAILLON (Associate Professor & Hospital Practitioner)

Clinical Advisor. Co-founder.

Jocelyne C. is a Microbiologist Associate Professor, Chair of the Hospital Committee of Anti-infectives. She is also Head of the teaching of Bacteriology at the Medicine Faculty of Nantes and Teacher of Anti-infective Therapeutics. Jocelyne got an Accreditation to supervise research in 2005 and is a member of the EA 3826 Research Unit.

 

Dr. Cédric JACQUELINE (Ph. D, Research Engineer)

Scientific Advisor. Co-founder.

Cédric J. holds a Master's degree of Therapeutic Pharmacology at the University of Paris VII in 2003. He works since 2007 in the Research Unit “Clinical and Experimental Therapeutics of Infections" (EA 3826) as the Responsible of the in vitro and in vivo studies; this activity enabled him to participate in the evaluation of numerous antibiotics that were in development (linezolid, ceftaroline, ceftolozane ...). Cédric has both a level 1 degree in Animal Experimentation and an Experimental Surgery degree.

Jocelyne, Gilles and Cédric are members of the French Society for Microbiology (SFM) and the American Society for Microbiology (ASM).

 

Prof Pr. Karim Asehnoune (Full Professor & Hospital Practitioner).

Clinical Adviser. Shareholder.

Karim A. is a Professor of Critical Care Medicine and Anesthesiology since 2009, leading the group host-pathogen interaction in the Research Unit “Clinical and Experimental Therapeutics of Infections" (EA 3826) since 2008. Karim specifically study the role of innate immunity for fighting against infections. He is the holder of 2 patents of which one proposes to treat immune suppression after severe trauma to protect patients against nosocomial infections.

 

 

Dr. Amir TOUAFEK (Pharm. D, MS Pharmaceutical Law and Affairs).

Responsible of Industrial and International Affairs. Co-founder.

Amir is an Industrial Pharmacist and holds postgraduate degrees in Pharmaceutical Law and Drug Quality and Safety. He has more than 10 years' experience in International Business Development.

 

 
LABORATORY TECHNICIANS

Cyndie DESESSARD - Engineer Assistant

Cyndie D. obtained her Engineer diploma in 2007. From 2008 to 2011, she has acquired skills in bacteriology (in vitro and in vivo) and in immunology within the Research Unit "Therapeutics Clinical and Experimental Infections" at the Nantes University. Cyndie has a level 2 degree in Animal Experimentation.

Xavier MAQUIN - Laboratory Technician

Xavier holds an Advanced Technician’s Certificate “Bioanalysis and Controls” at the Valin Secondary School of La Rochelle. Xavier M. performed its internship within the Research Unit “Clinical and Experimental Therapeutics of Infections" (EA 3826) and his thesis was on the sepsis model.

 

Our Partners

ATLANGRAM is based at Nantes (France), a city which offers opportunities to conduct collaborative projects with the Nantes University and a regional cluster (Atlanpole Biotherapies).

  • ATLANGRAM works closely with Nantes Hospital and the University’s teams
    • We conduct studies with Nantes University’s research teams, especially with the EA 3826 "Clinical and Experimental Therapeutics of Infections" (Pr. Potel, President of our Scientific Board).
    • An Infectious Diseases Department consisting of research units in bacteriology, virology, parasitology and immunology will bring together the teams for translational projects involving researchers, clinicians and academics (from the bench to the bedside and from the bedside to the bench). ATLANGRAM could participate in these projects.
    • MedQual: this information and resources center for the appropriate use of health products, has established a regional epidemiological surveillance in collaboration with a network of clinical laboratories. Through our partnership with MedQual, ATLANGRAM has a bank of hospital and community bacterial strains.
  • ATLANGRAM is a member of Atlanpole Biotherapies, a regional cluster. Atlanpole has a European Center for Business Innovation, and is partner of several clusters. It has conducted successful collaborations in R & D and several international projects.
  • Bpifrance mission is to fund and support innovation and business growth of SMEs at all critical stages of their life: creation, innovation, development, exportation, transmission and recovery. ATLANGRAM has received a grant from OSEO and Bpifrance Pays de la Loire.
  • Into the framework of support for the creation of enterprises in the sectors of industry and innovative technologies, the Région Pays de la Loire and TOTAL have granted to ATLANGRAM a financial assistance.